Clinical Trial Results:
A phase II, multi centre, pilot, randomised, ascending dose, double -blind, placebo controlled, dose titration study to determine the safety, maximum tolerated dose and preliminary evidence of efficacy of ralfinamide in the range of 80-320mg/day in patients with neuropathic pain.
Summary
|
|
EudraCT number |
2004-000557-35 |
Trial protocol |
GB |
Global completion date |
27 Apr 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 May 2020
|
First version publication date |
20 May 2020
|
Other versions |
|
Summary report(s) |
NW-1029-001-II-2003 synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.